PARLIAMENTARY WRITTEN QUESTION
Cystic Fibrosis: Drugs (16 October 2019)

To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of reimbursement arrangements for Vertex Pharmaceuticals products for cystic fibrosis in (a) Australia, (b) Germany, and (c) Scotland.

Asked by:
Sir John Hayes (Conservative)

The reimbursement arrangements in place for medicines in Scotland is a matter for the devolved administration. Assessments of the effectiveness of the arrangements for individual medicines in non-United Kingdom countries are not always straightforward as they have different population needs, health systems, and processes. Reimbursement arrangements are also often subject to commercial agreements that may be confidential.

Answered by:
Jo Churchill (Conservative)
24 October 2019